CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

30 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BPDGFRAD842VPredictiveSupportsResistanceGastrointestinal Stromal TumorImatinibCorless et al., 2005
BPDGFRAD842VPredictiveSupportsResistanceGastrointestinal Stromal TumorImatinibHeinrich et al., 2006
DPDGFRAD842IPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorCrenolanibHeinrich et al., 2012
DPDGFRAD842VPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorCrenolanibHeinrich et al., 2012
DPDGFRAD842YPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorCrenolanibHeinrich et al., 2012
DPDGFRAD842_I843delinsVMPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorCrenolanibHeinrich et al., 2012
BPDGFRAD842VPredictiveSupportsResistanceGastrointestinal Stromal TumorImatinibYoo et al., 2016
BPDGFRAD842VDiagnosticSupportsNegativeGastrointestinal Stromal TumorLasota et al., 2004
DPDGFRAI843DELPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorCrenolanibHeinrich et al., 2012
DPDGFRAD842VPredictiveSupportsResistanceGastrointestinal Stromal TumorImatinibHirota et al., 2003
DPDGFRAV561APredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorImatinibHirota et al., 2003
DPDGFRAAmplificationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSunitinibMcDermott et al., 2009
DPDGFRAP577SPredictiveSupportsSensitivity/ResponseMelanomaImatinib,CrenolanibDai et al., 2013
DPDGFRAR841KPredictiveSupportsSensitivity/ResponseMelanomaImatinib,CrenolanibDai et al., 2013
DPDGFRAH845YPredictiveSupportsSensitivity/ResponseMelanomaImatinib,CrenolanibDai et al., 2013
DPDGFRAG853DPredictiveSupportsSensitivity/ResponseMelanomaImatinib,CrenolanibDai et al., 2013
CPDGFRAMutationPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorImatinibHeinrich et al., 2003
CPDGFRAD842VPredictiveSupportsResistanceGastrointestinal Stromal TumorSunitinibHeinrich et al., 2008
DPDGFRAOverexpressionPredictiveSupportsSensitivity/ResponseRhabdomyosarcomaSunitinibMcDermott et al., 2009
DPDGFRAI843DELPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorImatinibHeinrich et al., 2003
DPDGFRAV561DPredictiveDoes Not SupportResistanceCancerImatinibHeinrich et al., 2003
DPDGFRAD842_H845DELDIMHPredictiveDoes Not SupportResistanceCancerImatinibHeinrich et al., 2003
DPDGFRAD842VPredictiveSupportsResistanceCancerImatinibHeinrich et al., 2003
CPDGFRAD842VPredictiveSupportsResistanceGastrointestinal Stromal TumorImatinibHeinrich et al., 2003
DPDGFRAV561DPredictiveDoes Not SupportResistanceCancerSunitinibHeinrich et al., 2008
DPDGFRAD842VPredictiveSupportsResistanceCancerSunitinibHeinrich et al., 2008
DPDGFRAD842VPredictiveSupportsResistanceCancerImatinib MesylateHeinrich et al., 2008
DPDGFRAV561DPredictiveDoes Not SupportResistanceCancerImatinib MesylateHeinrich et al., 2008
CPDGFRAV561DPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorImatinibHeinrich et al., 2008
CPDGFRAExon 18 MutationPredictiveDoes Not SupportSensitivity/ResponseGastrointestinal Stromal TumorImatinibHeinrich et al., 2008